Skip to content
Brilliant Blue Biosciences logoBrilliant BlueBiosciences
3
Question 3 of 3

What is my end goal?

The same reagent can be the right or wrong choice depending on what the experiment has to produce at the end. Efficiency, cost, reproducibility and regulatory fitness are traded against each other, and the acceptable trade depends entirely on the goal.

Answer matrix

Each answer, and the route it implies

Basic research / screening

Go to: High-efficiency lipid reagents, 96-well format, reverse transfection

Why: Speed and peak efficiency dominate; reagent cost per well is small

Watch out: Optimised for day-2 signal, not for long-term viability — do not carry the protocol into stable-line work unchanged

Stable cell line

Go to: Low-toxicity lipid or polymer, followed by 10–15 days of selection

Why: Surviving cells must proliferate afterwards, so gentle reagents win

Watch out: Split early and start selection promptly; prolonged high-dosage selection enriches resistant artefacts

Recombinant protein / bioproduction

Go to: PEI or process-grade polymer in suspension, scaled to the bioreactor

Why: Cost per litre and serum tolerance outweigh peak efficiency

Watch out: Process parameters, not the reagent, set the titre at scale — validate the medium and mixing as well

Viral vector manufacturing

Go to: PEIpro or PEI for multi-plasmid co-transfection in HEK293T

Why: Scale and regulatory documentation matter; the ratio of plasmids sets titre

Watch out: Harvest timing and plasmid quality drive empty-capsid fraction more than the reagent choice

Therapeutic / clinical development

Go to: GMP-grade or chemically defined carriers with endotoxin control

Why: Batch consistency and a documented chain of custody are non-negotiable

Watch out: Plan characterisation (size, encapsulation, potency) from the first development batch, not the last

Optimising for the wrong objective

Screening protocols are tuned for the highest possible signal on day two. That optimum frequently sits just above the toxicity cliff, which is harmless when the cells are discarded at day two and fatal when the plate is destined for two weeks of selection. If the endpoint is a stable line, the optimisation objective should be viability-weighted efficiency, not raw signal.

The same inversion appears at scale. A 24-well experiment optimises the reagent-to-DNA ratio for expression; a 100 L bioreactor is limited by mixing time, plasmid cost and the plasmid ratio that maximises functional titre. Choosing the bench-winning condition can actively reduce process yield.

What regulatory work changes

For a therapy, the carrier is part of the product. That means the material has to be traceable to a manufacturing lot, the process has to be reproducible across batches, and the release testing has to demonstrate identity, purity and potency. In-house PEI prepared from bulk powder cannot easily support that; a documented cGMP-equivalent reagent can.

It also changes the optimisation target: consistency across batches matters more than the best single result. A method that reliably delivers 70% efficiency is more valuable in development than one that delivers 90% on a good day.

  • Define acceptance criteria at the start of development — for example ≥70% reporter-positive and ≥85% viability.
  • Run at least three independent batches before claiming a process is established.
  • Hold a reference batch and compare every new lot against it.
  • Document raw material lot numbers, reagent expiry and the operator for every run.

Budgeting time and cost honestly

Electroporation has a higher consumable cost per sample but often removes an entire optimisation cycle, so it can be cheaper in total for primary cells. Lipid kits cost more per well but need less equipment. Polymer chemistry is the cheapest per litre and the most demanding to control. Match the cost structure to the volume of work, not the price of the box.

Decision rules

If this, then that

  • If Goal is a quick answerOptimise peak efficiency in 96-well format and accept a narrower viability window
  • If Goal is a stable lineOptimise viability-weighted efficiency, split early, and begin selection within 48 h
  • If Goal is production titreOptimise plasmid ratio and process parameters with a production-grade reagent
  • If Goal is clinical translationOptimise batch-to-batch consistency and characterisation from the first development batch
Laboratory bench with a 96-well plate, pipette, microfluidic chip and particle-size readout
From a 96-well screen to a GMP batch, the goal sets the optimisation target.

The other two questions

Provenance

References for this decision

Every protocol on this page was reconstructed from the manufacturer’s own documentation. Use these links to confirm concentrations, catalogue numbers and cell-line-specific variants before running the experiment.

  1. [1]Thermo Fisher — Transfection for stable cell line development
  2. [2]Polyplus — Solutions for bioproduction and therapeutic applications
  3. [3]Promega — Transfection applications overview

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through GMP supply.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes, licensing and GMP supply.InvestorsDownload our capabilities deckPlatform, pipeline milestones, manufacturing and partnership models in one PDF.